LunG and Melanoma canceR pAtients coVId19 Disease (GRAVID)

Completed

• Conditions: Lung Cancer; Covid-19

• Registration Number: NCT04344002
• Lead Sponsor: Spanish Lung Cancer Group

Brief Summary

This is a multi-centre study on lung cancer patients which experienced COVID-19. Information on clinical features, clinical course, management and outcomes will be collected for both, thoracic cancers and COVID-19 infection. Firstly, investigators will be registered in an online secure registry. After that, a protocol will be developed in order to collect clinical data for the research. It will also include I on the care organization or the perception of the patient and their family members.

The final stage will consist on retrospective data collection from patients. So, it is a retrospective study data collection, preceded by prospective data registry.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2020-04-09
• Study First Submitted QC: 2020-04-09
• Study First Posted: 2020-04-14
• Study Start: 2020-04-21
• Primary Completion: 2021-10-06
• Study Completion: 2021-10-06
• Status Verified: 2022-06
• Last Update Submitted: 2022-06-21
• Last Update Posted: 2022-06-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 886

Inclusion Criteria

• Patients diagnosed with lung cancer
• Patients who have contracted COVID-19 infection

Exclusion Criteria

• Patients diagnosed with lung cancer but no confirmation of COVID-19 infection.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Treatments received	From the diagnosis of the COVID until the patient is cured or dies, whichever comes first, assessed up to 5 years	Describe characteristics and evolution of Spanish patients preferably with lung cancer who contract COVID 19 infection with identification and study of factors of interest, as well as treatments received
Clinical data of lung cancer patients with COVID-19 diagnoses	From the diagnosis of the COVID until the patient is cured or dies, whichever comes first, assessed up to 5 years	Describe characteristics and evolution of Spanish patients preferably with lung cancer who contract COVID 19 infection with identification and study of factors of interest, as well as clinical data.
Prognostic factors	From the diagnosis of the COVID until the patient is cured or dies, whichever comes first, assessed up to 5 years	Describe characteristics and evolution of Spanish patients preferably with lung cancer who contract COVID 19 infection with identification and study of factors of interest, as well as prognostic factors.
Diagnosis data	From the diagnosis of the COVID until the patient is cured or dies, whichever comes first, assessed up to 5 years	Describe characteristics and evolution of Spanish patients preferably with lung cancer who contract COVID 19 infection with identification and study of factors of interest, as well as data about diagnosis

Trial Locations

Locations (75)

Complejo Hospitalario Universitario de Ferrol; 🇪🇸 Ferrol, A Coruña, Spain

H. Clínica Benidorm; 🇪🇸 Benidorm, Alicante, Spain

Hospital de Elche; 🇪🇸 Elche, Alicante, Spain

Hospital General Universitario de Elda; 🇪🇸 Elda, Alicante, Spain

Hospital de Torrevieja; 🇪🇸 Torrevieja, Alicante, Spain

Hospital Universitari Germans Trias i Pujol; 🇪🇸 Badalona, Barcelona, Spain

Cetir Centre Mèdic; 🇪🇸 Esplugues De Llobregat, Barcelona, Spain

Hospital General de Granollers; 🇪🇸 Granollers, Barcelona, Spain

Hospital Universitario de Galdakao; 🇪🇸 Galdakao, Bizkaia, Spain

Complejo Hospitalario de la Coruña; 🇪🇸 La Coruña, Coruña, Spain

Scroll for more (65 remaining)